Testing a new cell therapy for B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma (like diffuse large B-cell, follicular, or mantle cell lymphoma) that has come back or not responded to treatment.
- Your tumor has the CD19 or BCMA protein (this will be checked with a biopsy or previous test results).
- You have at least one tumor node bigger than 1.5 cm (about the size of a small grape) or a tumor outside the nodes bigger than 1 cm.
- You are in fairly good health (able to do most daily activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called MBS303 to see how safe it is and how well it works in adults with B-cell non-Hodgkin lymphoma (NHL) that has come back or did not respond to prior anti-CD20 treatment. It may help people who have few or no treatment options expected to improve survival.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests an experimental drug called SCTB35 for people with relapsed or refractory B-cell non-Hodgkin lymphoma that is CD20-positive. It aims to find a safe dose and see how well it works.
This trial tests a new treatment called JCXH-213 for people with B-cell non-Hodgkin lymphoma that came back or didn't get better after previous treatment. It aims to see if the treatment is safe and works against the cancer.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has come back after at least two prior treatments. It may help if you've already had rituximab or a similar antibody therapy.
Hear when a new Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.